IP Library Granted Patent US 12,168,108
Granted Patent B2
US 12,168,108 · App. 18/379,505 · Granted Dec 17, 2024

Balloon catheters for body lumens

Inventors: Lixiao Wang (Henderson, NV); Peter Barnett (Shakopee, MN)
Assignee: Urotronic, Inc.
A61M29/02A61L29/16A61M25/10A61K31/337A61L29/08A61L2300/41A61L2300/602A61L2300/606A61L2300/802A61L2420/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,108
App. No.
18/379,505
Granted
Dec 17, 2024
Kind
B2
Abstract

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Claims (29)

1. A balloon catheter comprising:

an elongated balloon; and

a coating layer overlying external surfaces of the balloon, the coating layer comprising at least one additive and an initial drug load of a therapeutic agent;

wherein the coating layer is hydrated.

2. The balloon catheter of claim 1 , wherein the coating layer is hydrated with and comprises a solution comprising water or saline.

3. The balloon catheter of claim 2 , wherein the coating layer is hydrated with the solution outside the body.

4. The balloon catheter of claim 2 , wherein the coating layer is hydrated with a flushing fluid comprising the solution inside a body lumen stricture or stenosis.

5. The balloon catheter of claim 4 , wherein the body lumen stricture or stenosis is in a nonvascular lumen.

6. The balloon catheter of claim 4 , wherein the flushing fluid is added to the body lumen stricture or stenosis.

7. The balloon catheter of claim 2 , wherein the coating layer is soaked or flushed with the solution to form the coating layer hydrated with the solution.

8. The balloon catheter of claim 2 , wherein the coating layer is soaked or flushed with the solution for a time of at least 1 minute to form the coating layer hydrated with the solution.

9. The balloon catheter of claim 1 , wherein the balloon is in an uninflated state.

10. The balloon catheter of claim 1 , wherein the balloon catheter is in a stricture or stenosis in a body lumen.

11. The balloon catheter of claim 10 , wherein the stricture or stenosis is in a nonvascular body lumen.

12. The balloon catheter of claim 10 , wherein the stricture or stenosis is a gastrointestinal body lumen.

13. The balloon catheter of claim 10 , wherein the stricture or stenosis is in the esophagus, airways, sinus, trachea, colon, biliary tract, stomach, small intestine, duodenum, jejunum, ileum, rectum, large intestine, urinary tract, prostatic urethra, urethra, or ureter.

14. The balloon catheter of claim 1 , wherein the balloon catheter is outside the body.

15. The balloon catheter of claim 1 , wherein a ratio by weight of the therapeutic agent to a total weight of the one or more additives in the coating layer is from 2 to 6, and/or wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the balloon.

16. The balloon catheter of claim 1 , wherein the one or more additives in the coating layer comprise N-acetylglucosamine, N-octyl-D-gluconamide, N-nonanoyl-N-methylglycamine, N-octanoyl-N-methyl glutamine, C6-ceramide, dihydro-C6-ceramide, cerabroside, sphingomyelin, galaclocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octonoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic/capric diglycerides, PEG8 caprylic/capric glycerides, PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monocaproate, monolaurin, monocaprin, monocaprylin, monomyristin, monopalmitolein, monoolein, creatine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthosine, xanthosine monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N′-bis(hydroxymethyl) urea, pentaerythritol propoxylate, pentaerythritol propoxylate/ethoxylate, glycerol ethoxylate, glycerol propoxylate, trimethylolpropane ethoxylate, pentaerythritol, dipentaerythritol, crown ether, 18-crown-6, 15-crown-5, 12-crown-4, or combinations thereof.

17. The balloon catheter of claim 1 , wherein the one or more additives in the coating layer comprises pentaerythritol ethoxylate (15/4), pentaerythritol ethoxylate (3/4), or a combination thereof.

18. The balloon catheter of claim 1 , wherein the therapeutic agent comprises paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof.

19. A balloon catheter comprising:

an elongated balloon; and

a coating layer overlying external surfaces of the balloon, the coating layer comprising at least one additive and an initial drug load of a therapeutic agent;

wherein the coating layer is hydrated with and comprises a solution comprising water or saline, and wherein the coating layer is soaked with the solution outside the body.

20. A balloon catheter comprising:

an elongated balloon; and

a coating layer overlying external surfaces of the balloon, the coating layer comprising at least one additive and an initial drug load of a therapeutic agent;

wherein the coating layer is soaked with and comprises a solution comprising water or saline, and wherein the coating layer is hydrated with a flushing fluid comprising the solution inside a body lumen stricture or stenosis.

Assignments (2)
SECURITY INTEREST Recorded Jul 23, 2024
From: NOVONATE INC.; PELVALON, INC.; UROTRONIC, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 068057/0959 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2023
From: WANG, LIXIAO; BARNETT, PETER
To: UROTRONIC, INC.
Reel/Frame 065245/0169 →
Continuity (11)
Continuation 18097698 · Jan 17, 2023
Continuation 17843208 · Jun 17, 2022
Continuation 17108517 · Dec 1, 2020
Continuation 16519677 · Jul 23, 2019
Continuation In Part PCTUS2018031083 · May 4, 2018
Continuation In Part 15568614
Continuation In Part 14438327
Provisional Application 62502212 · May 5, 2017
Provisional Application 62152559 · Apr 24, 2015
Provisional Application 61795790 · Oct 26, 2012
Related Publication 20240042183A1 · Feb 8, 2024
Cited By (1)
US 12,383,710